# Argireline

> A topical "neurocosmetic" hexapeptide that mimics SNAP-25 to soften expression wrinkles — often called topical Botox.

- Also known as: Acetyl Hexapeptide-8, Acetyl Hexapeptide-3, Ac-EEMQRR-NH2
- Class: Cosmetic
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/argireline

## Overview

Argireline (acetyl hexapeptide-8) is a synthetic hexapeptide widely used in anti-aging cosmetics. It mimics the N-terminal end of SNAP-25, a protein in the SNARE complex that nerve endings use to release the signals that make facial muscles contract. By competing in that complex, Argireline is proposed to reduce the muscle contractions behind expression lines — the reason it is marketed as a topical, needle-free alternative to botulinum toxin.

Argireline was the peptide that launched the "neurocosmetic" category — topical ingredients that borrow the logic of botulinum toxin without the toxin. Its six-residue, N-acetylated sequence mimics the very end of SNAP-25, one of the SNARE proteins a nerve terminal uses to dock and release its signaling vesicles. By slotting into that machinery, Argireline is proposed to blunt the release that tells a facial muscle to contract, so repeated expressions crease the skin less.

In practice it is a cosmetic-formulation ingredient, applied to the skin in serums and creams rather than injected, and its measured effects are modest and surface-level compared with injected botulinum toxin. It sits in this catalog alongside the other skin peptides — the copper peptides and matrixyl — as a reference entry: a well-defined, widely sold compound whose mechanism is genuinely interesting even where the marketing outruns the evidence. It is a cosmetic ingredient, not an FDA-approved drug.

## Mechanism

Mimics the N-terminus of SNAP-25, competitively interfering with SNARE-complex assembly and reducing neurotransmitter release at the neuromuscular junction — dampening the muscle contractions that form expression wrinkles.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C35H62N14O11S |
| Molecular weight | 887 Da |
| CAS number | 616204-22-9 |
| PubChem CID | [71587772](https://pubchem.ncbi.nlm.nih.gov/compound/71587772) |

## Sequence

```
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2
```

## Research areas

Studied in: Topical anti-aging, Expression-line reduction, Cosmetic formulation.

## Key research

- SNAP-25 mimic — its acetylated hexapeptide sequence imitates the SNAP-25 N-terminus, competing in the SNARE complex that drives neurotransmitter release.
- The "topical Botox" concept — marketed as a needle-free way to soften expression lines by reducing muscle contraction; effects are modest and surface-level.
- Cosmetic ingredient — formulated into topical serums and creams (INCI: Acetyl Hexapeptide-8), not injected.
- Well-characterized peptide — a defined synthetic hexapeptide, in contrast to the marketing language around it.
- Not an FDA-approved drug — a cosmetic ingredient; this page is a research and educational reference.

## Storage, handling & synthesis

**Synthesis.** Argireline (acetyl hexapeptide-8) is a short N-acetylated, C-terminally amidated hexapeptide made by routine solid-phase synthesis. The two end modifications are the defining steps; the sequence is otherwise straightforward, and the acetate counterion and residual solvents dominate cosmetic-grade QC.

## FAQs

### What is Argireline?

Argireline (acetyl hexapeptide-8) is a synthetic hexapeptide used in anti-aging cosmetics that mimics SNAP-25 to reduce the muscle contractions behind expression wrinkles.

### Is it really "topical Botox"?

It borrows the same SNARE / SNAP-25 logic as botulinum toxin, but it is applied topically and its effects are modest and superficial — not equivalent to injected Botox.

### How does it compare with matrixyl?

Argireline targets muscle-contraction signaling (expression lines); matrixyl (a palmitoyl peptide) signals fibroblasts to make more collagen. They address different aspects of skin aging.

### Is Argireline approved?

It is a cosmetic ingredient, not an FDA-approved drug. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning Argireline, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [A Clinical Trial to Evaluate the Effects of an Eye Serum on Improving the Appearance of the Periorbital Area](https://clinicaltrials.gov/study/NCT06143033) — COMPLETED · NA · NCT06143033
- [Investigating the Wrinkle Reduction Potential of a Novel Compounded Skin Care Cream](https://clinicaltrials.gov/study/NCT03878381) — COMPLETED · EARLY_PHASE1 · NCT03878381
- [Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin](https://clinicaltrials.gov/study/NCT02597777) — COMPLETED · NA · NCT02597777
- [Acetyl Hexapeptide-8 for Blepharospasm](https://clinicaltrials.gov/study/NCT01750346) — TERMINATED · PHASE2 · NCT01750346
- [A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm](https://clinicaltrials.gov/study/NCT00942851) — COMPLETED · PHASE1, PHASE2 · NCT00942851
- [Argireline in Treatment of Periorbital Wrinkles](https://clinicaltrials.gov/study/NCT01381484) — COMPLETED · PHASE3 · NCT01381484

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/argireline
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.